2,813 results match your criteria Breast Cancer Res.[Journal]


Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study.

Breast Cancer Res 2019 Apr 18;21(1):52. Epub 2019 Apr 18.

Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 W 168th St, New York, NY, 10032, USA.

Background: The use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced breast cancer risk, but it is not known if this association extends to women at familial or genetic risk. We examined the association between regular NSAID use and breast cancer risk using a large cohort of women selected for breast cancer family history, including 1054 BRCA1 or BRCA2 mutation carriers.

Methods: We analyzed a prospective cohort (N = 5606) and a larger combined, retrospective and prospective, cohort (N = 8233) of women who were aged 18 to 79 years, enrolled before June 30, 2011, with follow-up questionnaire data on medication history. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1135-yDOI Listing
April 2019
1 Read

BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells.

Breast Cancer Res 2019 Apr 17;21(1):51. Epub 2019 Apr 17.

Department of Biochemistry & Molecular Medicine, School of Medicine & Health Sciences, The George Washington University, Washington, DC, 20037, USA.

Background: BRCA1-associated breast cancer originates from luminal progenitor cells. BRCA1 functions in multiple biological processes, including double-strand break repair, replication stress suppression, transcriptional regulation, and chromatin reorganization. While non-malignant cells carrying cancer-predisposing BRCA1 mutations exhibit increased genomic instability, it remains unclear whether BRCA1 haploinsufficiency affects transcription and chromatin dynamics in breast epithelial cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1132-1DOI Listing

Association between prediagnostic leukocyte telomere length and breast cancer risk: the Singapore Chinese Health Study.

Breast Cancer Res 2019 Apr 17;21(1):50. Epub 2019 Apr 17.

Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, UPMC Cancer Pavilion, Suite 4C, 5150 Centre Avenue, Pittsburgh, PA, 15232, USA.

Background: Telomeres and telomerase play key roles in the chromosomal maintenance and stability. Recent epidemiological studies have shown that longer telomeres are associated with increased risk of several cancer types. However, epidemiological data for telomere length and risk of breast cancer are sparse. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1133-0DOI Listing

The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.

Breast Cancer Res 2019 Apr 3;21(1):47. Epub 2019 Apr 3.

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, 55905, USA.

Background: Our previous genome-wide association study using the MA.27 aromatase inhibitors adjuvant trial identified SNPs in the long noncoding RNA MIR2052HG associated with breast cancer-free interval. MIR2052HG maintained ERα both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated ERα degradation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1130-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448248PMC
April 2019
1 Read

Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.

Breast Cancer Res 2019 Apr 3;21(1):48. Epub 2019 Apr 3.

General Internal Medicine Section, San Francisco Veterans Affairs Medical Center & Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.

Background: Obesity and elevated breast density are common risk factors for breast cancer, and their effects may vary by estrogen receptor (ER) subtype. However, their joint effects on ER subtype-specific risk are unknown. Understanding this relationship could enhance risk stratification for screening and prevention. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1129-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448282PMC
April 2019
7 Reads

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?

Breast Cancer Res 2019 Apr 3;21(1):49. Epub 2019 Apr 3.

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1134-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448267PMC
April 2019
4 Reads

Genomic signature of parity in the breast of premenopausal women.

Breast Cancer Res 2019 Mar 28;21(1):46. Epub 2019 Mar 28.

The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center - Temple University Health System, 333 Cottman Ave, P2051, Philadelphia, PA, 19111, USA.

Background: Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal women. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1128-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438043PMC
March 2019
4 Reads

Correction to: ECM1 regulates cell proliferation and trastuzumab resistance through activation of EGF-signaling.

Breast Cancer Res 2019 Mar 26;21(1):45. Epub 2019 Mar 26.

Department of Life Science, Hanyang University, Seoul, KS013, Republic of Korea.

After the publication of this work [1] errors were found in Figs. 1a and 5d. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1106-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434869PMC

Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study.

Breast Cancer Res 2019 Mar 22;21(1):44. Epub 2019 Mar 22.

Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43-45, DK-8200, Aarhus N, Denmark.

Background: Hypothyroidism may occur as a late effect of breast cancer-directed treatment, particularly after radiotherapy, but little is known whether hypothyroidism affects the prognosis after breast cancer. We investigated the association between hypothyroidism and breast cancer recurrence, and all-cause mortality.

Methods: In this population-based cohort study, we used national medical registries to identify all Danish women 35 years or older diagnosed with stage I-III, operable breast cancer between 1996 and 2009. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1122-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431068PMC
March 2019
1 Read

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer.

Breast Cancer Res 2019 Mar 21;21(1):43. Epub 2019 Mar 21.

The Kinghorn Cancer Centre, Garvan Institute of Medical Research, 370 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia.

Background: The oncogenic receptor tyrosine kinase (RTK) ERBB2 is known to dimerize with other EGFR family members, particularly ERBB3, through which it potently activates PI3K signalling. Antibody-mediated inhibition of this ERBB2/ERBB3/PI3K axis has been a cornerstone of treatment for ERBB2-amplified breast cancer patients for two decades. However, the lack of response and the rapid onset of relapse in many patients now question the assumption that the ERBB2/ERBB3 heterodimer is the sole relevant effector target of these therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1127-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429830PMC

Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model.

Breast Cancer Res 2019 Mar 19;21(1):42. Epub 2019 Mar 19.

Department of Population Health, New York University School of Medicine, 650 First Avenue, New York, NY, 10016, USA.

Background: Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and testosterone have been positively associated with breast cancer risk in prospective studies. We assessed whether adding AMH and/or testosterone to the Gail model improves its prediction performance for women aged 35-50. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1126-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425605PMC
March 2019
1 Read

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Breast Cancer Res 2019 03 11;21(1):39. Epub 2019 Mar 11.

Breast Cancer Research Centre-WA, Perth & Curtin University, Nedlands, Australia.

Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that inhibits PI3K/Akt and MAPK signaling pathways after HER2 receptor activation. The ExteNET study showed that neratinib significantly improved 5-year invasive disease-free survival (iDFS) in women who completed trastuzumab-based adjuvant therapy for early breast cancer (EBC). We assessed the prognostic and predictive significance of PIK3CA alterations in patients in ExteNET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1115-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417207PMC
March 2019
8 Reads

Impact of obesity on breast cancer recurrence and minimal residual disease.

Breast Cancer Res 2019 03 13;21(1):41. Epub 2019 Mar 13.

Department of Cancer Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

Background: Obesity is associated with an increased risk of breast cancer recurrence and cancer death. Recurrent cancers arise from the pool of residual tumor cells, or minimal residual disease (MRD), that survives primary treatment and persists in the host. Whether the association of obesity with recurrence risk is causal is unknown, and the impact of obesity on MRD and breast cancer recurrence has not been reported in humans or in animal models. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1087-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416940PMC
March 2019
7 Reads

Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies.

Breast Cancer Res 2019 03 12;21(1):40. Epub 2019 Mar 12.

Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA, 02115, USA.

Background: Epidemiologic data suggest that parity increases risk of hormone receptor-negative breast cancer and that breastfeeding attenuates this association. Prospective data, particularly on the joint effects of higher parity and breastfeeding, are limited.

Methods: We investigated parity, breastfeeding, and breast cancer risk by hormone-receptor (estrogen (ER) and progesterone receptor (PR)) and molecular subtypes (luminal A, luminal B, HER2-enriched, and basal-like) in the Nurses' Health Study (NHS; 1976-2012) and NHSII (1989-2013). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1119-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416887PMC
March 2019
5 Reads

Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study.

Breast Cancer Res 2019 03 8;21(1):38. Epub 2019 Mar 8.

Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.

Background: High background parenchymal uptake (BPU) on molecular breast imaging (MBI) has been identified as a breast cancer risk factor. We explored the feasibility of offering a short-term intervention of low-dose oral tamoxifen to women with high BPU and examined whether this intervention would reduce BPU.

Methods: Women with a history of high BPU and no breast cancer history were invited to the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1120-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408779PMC
March 2019
1 Read

GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.

Breast Cancer Res 2019 03 7;21(1):37. Epub 2019 Mar 7.

Department of Translational Molecular Pathology, UT MD Anderson Cancer Center, Houston, TX, USA.

Background: Triple-negative breast cancers (TNBCs), which lack receptors for estrogen, progesterone, and amplification of epidermal growth factor receptor 2, are highly aggressive. Consequently, patients diagnosed with TNBCs have reduced overall and disease-free survival rates compared to patients with other subtypes of breast cancer. TNBCs are characterized by the presence of cancer cells with mesenchymal properties, indicating that the epithelial to mesenchymal transition (EMT) plays a major role in the progression of this disease. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1125-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407242PMC
March 2019
10 Reads

Separation of breast cancer and organ microenvironment transcriptomes in metastases.

Breast Cancer Res 2019 03 6;21(1):36. Epub 2019 Mar 6.

Department of Pathology, Virginia Commonwealth University, Richmond, VA, USA.

Background: The seed and soil hypothesis was proposed over a century ago to describe why cancer cells (seeds) grow in certain organs (soil). Since then, the genetic properties that define the cancer cells have been heavily investigated; however, genomic mediators within the organ microenvironment that mediate successful metastatic growth are less understood. These studies sought to identify cancer- and organ-specific genomic programs that mediate metastasis. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1123-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404325PMC
March 2019
3 Reads

Updating the role of obesity and cholesterol in breast cancer.

Breast Cancer Res 2019 03 1;21(1):35. Epub 2019 Mar 1.

Breast Cancer Department, MD Anderson Cancer Center, Arturo Soria 270, 280339, Madrid, Spain.

Background: Breast cancer is the second most common cause of cancer-related death among women. Advances in our understanding of the disease have translated into better diagnostics and more effective therapeutics, leading to earlier detection and improved outcomes. Several studies have pointed at lifestyle and environmental factors as contributory for the onset and progression of the disease. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1124-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397485PMC
March 2019
4 Reads

The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.

Breast Cancer Res 2019 02 28;21(1):34. Epub 2019 Feb 28.

Department of Oncology and Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden.

Background: Use of cyclin D1 (CCND1) gene amplification as a breast cancer biomarker has been hampered by conflicting assessments of the relationship between cyclin D1 protein levels and patient survival. Here, we aimed to clarify its prognostic and treatment predictive potential through comprehensive long-term survival analyses.

Methods: CCND1 amplification was assessed using SNP arrays from two cohorts of 1965 and 340 patients with matching gene expression array and clinical follow-up data of over 15 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1121-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394106PMC
February 2019
1 Read

The distribution and determinants of mammographic density measures in Western Australian aboriginal women.

Breast Cancer Res 2019 02 28;21(1):33. Epub 2019 Feb 28.

Centre for Genetic Origins of Health and Disease, School of Biomedical Science, Curtin University and The University of Western Australia, Perth, Western Australia, Australia.

Background: Mammographic density (MD) is an established risk factor for breast cancer. There are significant ethnic differences in MD measures which are consistent with those for corresponding breast cancer risk. This is the first study investigating the distribution and determinants of MD measures within Aboriginal women of Western Australia (WA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1113-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393976PMC
February 2019
1 Read

Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial.

Breast Cancer Res 2019 02 27;21(1):32. Epub 2019 Feb 27.

Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Deerfield Beach, FL, USA.

Background: We characterized patterns of occurrence and the impact of neratinib-associated diarrhea in the absence of protocol-directed antidiarrheal prophylaxis or a formal diarrhea management plan using data from Extended Adjuvant Treatment of Breast Cancer with Neratinib (ExteNET).

Methods: ExteNET is a multicenter, double-blind, placebo-controlled, randomized phase III trial involving community-based and academic institutions in 40 countries. Women with HER2-positive early-stage breast cancer with prior standard primary therapy and trastuzumab-based (neo)adjuvant therapy were randomized to neratinib 240 mg/day or placebo for 12 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1112-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391844PMC
February 2019

Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment.

Breast Cancer Res 2019 02 27;21(1):31. Epub 2019 Feb 27.

Department of Cancer Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

Introduction: In a cancer-free environment in the adult, the skeleton continuously undergoes remodeling. Bone-resorbing osteoclasts excavate erosion cavities, and bone-depositing osteoblasts synthesize osteoid matrix that forms new bone, with no net bone gain or loss. When metastatic breast cancer cells invade the bone, this balance is disrupted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1117-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391840PMC
February 2019

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.

Breast Cancer Res 2019 02 22;21(1):30. Epub 2019 Feb 22.

Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Background: The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60-80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1118-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387478PMC
February 2019
1 Read

AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.

Breast Cancer Res 2019 02 21;21(1):29. Epub 2019 Feb 21.

Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, David Geffen UCLA School of Medicine, and UCLA Jonsson Comprehensive Cancer Center, 1748 E. 118th Street, Los Angeles, CA, 90059, USA.

Triple-negative breast cancer (TNBC) is an aggressive subset of breast carcinomas that lack expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Unlike other breast cancer subtypes, targeted therapy is presently unavailable for patients with TNBC. In spite of initial responses to chemotherapy, drug resistance tends to develop rapidly and the prognosis of metastatic TNBC is poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1107-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385460PMC
February 2019
2 Reads

Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.

Breast Cancer Res 2019 02 18;21(1):28. Epub 2019 Feb 18.

Translational Cancer Research Unit, GZA Hospitals & CORE, MIPRO, University of Antwerp, Antwerp, Belgium.

Background: Inflammatory breast cancer (IBC) is a rare and rapidly progressive form of invasive breast cancer. The aim of this study was to explore the clinical evolution, stromal tumour-infiltrating lymphocytes (sTIL) infiltration and programmed death-ligand 1 (PD-L1) expression in a large IBC cohort.

Patients And Methods: Data were collected prospectively from patients with IBC as part of an international collaborative effort since 1996. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1108-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380068PMC
February 2019
5 Reads

MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.

Breast Cancer Res 2019 02 18;21(1):27. Epub 2019 Feb 18.

Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, Bethesda, MD, 20892-1361, USA.

Background: TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity against normal cells. Despite an attractive mechanism of action, previous clinical efforts to use TRAIL receptor agonists have been unsuccessful. In this study, we examined MEDI3039, a highly potent multivalent DR5 agonist, in breast cancer cell lines and in vivo models. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1116-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380056PMC
February 2019
1 Read

Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells.

Breast Cancer Res 2019 02 17;21(1):26. Epub 2019 Feb 17.

Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.

After the publication of this work [1] errors were noticed in Figs. 1a, 6a, and 8a-in which the β-actin bands were mistakenly presented. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1105-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378715PMC
February 2019
1 Read

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Breast Cancer Res 2019 02 15;21(1):25. Epub 2019 Feb 15.

Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.

Background: Although parity and age at first pregnancy are among the most known extrinsic factors that modulate breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in depth. Recent data suggest that pregnancy-induced tumor protection is different according to breast cancer subtypes, with parity and young age at first pregnancy being associated with a marked reduction in the risk of developing luminal subtype but not triple negative breast cancer. In this study, we investigated the imprint of parity and age at first pregnancy on the pattern of somatic mutations, somatic copy number alterations, transcriptomic profiles, and tumor immune microenvironment by assessing tumor-infiltrating lymphocytes (TILs) levels of subsequent breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1111-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377756PMC
February 2019
1 Read

Airborne metals and polycyclic aromatic hydrocarbons in relation to mammographic breast density.

Breast Cancer Res 2019 02 13;21(1):24. Epub 2019 Feb 13.

Departments of Surgery and Radiology, University of Vermont, Burlington, VT, USA.

Background: Breast density is strongly related to breast cancer. Identifying associations between environmental exposures and density may elucidate relationships with breast cancer. Metals and polycyclic aromatic hydrocarbons (PAHs) may influence breast density via oxidative stress or endocrine disruption. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1110-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373138PMC
February 2019
2 Reads

CXCL17-derived CD11bGr-1 myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.

Breast Cancer Res 2019 02 12;21(1):23. Epub 2019 Feb 12.

Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.

Background: Metastasis is the major cause of death from breast cancer. Colonization and adaption of metastatic cells in distant organs is a rate-limiting step of the cancer spreading. The underlying mechanisms responsible for the colonization of breast cancer to lung metastatic niches are not fully understood. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1114-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373011PMC
February 2019
1 Read

Targeted mutation detection in breast cancer using MammaSeq™.

Breast Cancer Res 2019 02 8;21(1):22. Epub 2019 Feb 8.

Department of Pharmacology and Chemical Biology, and Human Genetics, UPMC Hillman Cancer Center, Magee-Womens Research Institute, University of Pittsburgh, 204 Craft Avenue, Pittsburgh, PA, 15213, USA.

Background: Breast cancer is the most common invasive cancer among women worldwide. Next-generation sequencing (NGS) has revolutionized the study of cancer across research labs around the globe; however, genomic testing in clinical settings remains limited. Advances in sequencing reliability, pipeline analysis, accumulation of relevant data, and the reduction of costs are rapidly increasing the feasibility of NGS-based clinical decision making. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1102-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368740PMC
February 2019
10 Reads

Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.

Breast Cancer Res 2019 02 6;21(1):21. Epub 2019 Feb 6.

Liquid biopsy and metastasis research group, GENYO, Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government PTS, Granada, Avenida de la Ilustración 114, 18016, Granada, Spain.

Background: Breast cancer patients under neoadjuvant chemotherapy includes a heterogeneous group of patients who eventually develop distal disease, not detectable by current methods. We propose the use of exosomal miRNAs and circulating tumor cells as diagnostic and predictive biomarkers in these patients.

Methods: Fifty-three breast cancer women initially diagnosed with localized breast cancer under neoadjuvant chemotherapy were prospectively enrolled in this study. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1109-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366103PMC
February 2019
3 Reads

MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.

Breast Cancer Res 2019 02 1;21(1):20. Epub 2019 Feb 1.

Division of Oncology, Department of Internal Medicine, Medical University of Graz (MUG), Graz, Austria.

Background: Non-coding RNAs and especially microRNAs have been discovered to act as master regulators of cancer initiation and progression. The aim of our study was to discover and characterize the function of yet functionally uncharacterized microRNAs in human breast carcinogenesis.

Methods: In an unbiased approach, we utilized an established model system for breast cancer (BC) stem cell formation ("mammosphere assay") to identify whole miRNome alterations in breast carcinogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1104-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359814PMC
February 2019

A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.

Breast Cancer Res 2019 01 31;21(1):18. Epub 2019 Jan 31.

Toronto General Research Institute - University Health Network, 67 College Street, Rm. 407, Toronto, Ontario, M5G 2M1, Canada.

Background: Triple-negative breast cancer (TNBC) represents a heterogeneous group of ER- and HER2-negative tumors with poor clinical outcome. We recently reported that Pten-loss cooperates with low expression of microRNA-145 to induce aggressive TNBC-like lesions in mice. To systematically identify microRNAs that cooperate with PTEN-loss to induce aggressive human BC, we screened for miRNAs whose expression correlated with PTEN mRNA levels and determined the prognostic power of each PTEN-miRNA pair alone and in combination with other miRs. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1098-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357448PMC
January 2019
2 Reads

Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).

Breast Cancer Res 2019 01 31;21(1):19. Epub 2019 Jan 31.

Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center; Salzburg Cancer Research Institute - Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Paracelsus Medical University, Salzburg, Austria.

Background: Patients with early breast cancer (EBC) achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) have a favorable prognosis. Breast surgery might be avoided in patients in whom the presence of residual tumor can be ruled out with high confidence. Here, we investigated the diagnostic accuracy of contrast-enhanced MRI (CE-MRI) in predicting pCR and long-term outcome after NACT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1091-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357474PMC
January 2019
1 Read

Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.

Breast Cancer Res 2019 01 30;21(1):17. Epub 2019 Jan 30.

Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA, 90095-1714, USA.

Background: Cancer is frequently associated with tumor-related anemia, and many chemotherapeutic agents impair hematopoiesis, leading to impaired quality of life for affected patients. The use of erythropoiesis-stimulating agents has come under scrutiny after prospective clinical trials using recombinant erythropoietin to correct anemia reported increased incidence of thromboembolic events and cancer-related deaths. Furthermore, previous preclinical reports indicated expansion of the pool of breast cancer-initiating cells when erythropoietin was combined with ionizing radiation. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1100-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6354373PMC
January 2019
7 Reads

Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies.

Breast Cancer Res 2019 01 29;21(1):16. Epub 2019 Jan 29.

MPH Education Center, Shantou University Medical College, Shantou, Guangdong, China.

Background: Epidemiologic evidence suggests that certain dietary patterns were associated with breast cancer risk, but the results have been inconclusive. We assessed the associations between different dietary patterns and the risk of breast cancer by conducting a meta-analysis of observational studies.

Methods: Relevant articles were searched in PubMed, Embase, and Cochrane library databases through September 2017. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-019-1096-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6352362PMC
January 2019
8 Reads

Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.

Breast Cancer Res 2019 01 25;21(1):14. Epub 2019 Jan 25.

Department of Epidemiology, Lebanon, USA.

Background: BRCA1-mutated cancers exhibit deficient homologous recombination (HR) DNA repair, resulting in extensive copy number alterations and genome instability. HR deficiency can also arise in tumors without a BRCA1 mutation. Compared with other breast tumors, HR-deficient, BRCA1-like tumors exhibit worse prognosis but selective chemotherapeutic sensitivity. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1090-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347811PMC
January 2019
8 Reads

p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.

Breast Cancer Res 2019 01 25;21(1):13. Epub 2019 Jan 25.

Institut Curie, PSL Research University, CNRS, UMR144, 26 rue d'Ulm, F-75005, Paris, France.

Background: The adult mammary epithelium is composed of basal and luminal cells. The luminal lineage comprises two major cell populations, positive and negative for estrogen and progesterone receptors (ER and PR, respectively), both containing clonogenic progenitor cells. Deregulated ER/PR luminal progenitor cells are suspected to be at the origin of basal-type triple-negative (TNBC) breast cancers, a subtype frequently associated with loss of P53 function and MET signaling hyperactivation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1101-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346556PMC
January 2019
16 Reads

Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer.

Breast Cancer Res 2019 01 24;21(1):12. Epub 2019 Jan 24.

Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada.

Background: Limited understanding of the cancer biology of metastatic sites is a major factor contributing to poor outcomes in cancer patients. The regional lymph nodes are the most common site of metastasis in most solid cancers and their involvement is a strong predictor of relapse in breast cancer (BC). We have previously shown that ezrin, a cytoskeletal-membrane linker protein, is associated with lymphovascular invasion and promotes metastatic progression in BC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1079-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345049PMC
January 2019

Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer.

Breast Cancer Res 2019 01 23;21(1):11. Epub 2019 Jan 23.

Metastasis Research Laboratory, GIGA-Cancer, University of Liège (ULiège), Pathology Tour, +4 level, Building 23, Avenue Hippocrate 13, 4000, Liège, Belgium.

Background: Elevated aerobic glycolysis rate is a biochemical alteration associated with malignant transformation and cancer progression. This metabolic shift unavoidably generates methylglyoxal (MG), a potent inducer of dicarbonyl stress through the formation of advanced glycation end products (AGEs). We have previously shown that the silencing of glyoxalase 1 (GLO1), the main MG detoxifying enzyme, generates endogenous dicarbonyl stress resulting in enhanced growth and metastasis in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1095-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343302PMC
January 2019

Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study.

Breast Cancer Res 2019 01 22;21(1). Epub 2019 Jan 22.

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Nobels Väg 12A, 171 77, Stockholm, Sweden.

Background: High mammographic density is associated with breast cancer and with delayed detection. We have examined whether localized density, at the site of the subsequent cancer, is independently associated with being diagnosed with a large-sized or interval breast cancer.

Methods: Within a prospective cohort of 63,130 women, we examined 891 women who were diagnosed with incident breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1099-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341532PMC
January 2019
1 Read

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.

Breast Cancer Res 2019 01 22;21(1). Epub 2019 Jan 22.

Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, NO-0379, Oslo, Norway.

Background: Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable of reshaping the tumor microenvironment, turning "cold" tumors "hot" through a significant increase in tumor-infiltrating lymphocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1092-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343247PMC
January 2019

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.

Breast Cancer Res 2019 01 22;21(1):10. Epub 2019 Jan 22.

Cancer Research UK Edinburgh Centre and Division of Pathology Laboratory, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.

Background: Tumour hypoxia is a driver of breast cancer progression associated with worse prognosis and more aggressive disease. The cellular response to hypoxia is mediated by the hypoxia-inducible transcription factors HIF-1 and HIF-2, whose transcriptional activity is canonically regulated through their oxygen-labile HIF-α subunits. These are constitutively degraded in the presence of oxygen; however, HIF-1α can be stabilised, even at high oxygen concentrations, through the activation of HER receptor signalling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-019-1097-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343358PMC
January 2019

Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP).

Breast Cancer Res 2019 01 17;21(1). Epub 2019 Jan 17.

Institut de Pharmacologie et de Biologie Structurale (IPBS), Université de Toulouse, CNRS, UPS, UMR 5089, 205 route de Narbonne, 31077, Toulouse, France.

Introduction: Clinical studies suggest that obesity, in addition to promoting breast cancer aggressiveness, is associated with a decrease in chemotherapy efficacy, although the mechanisms involved remain elusive. As chemotherapy is one of the main treatments for aggressive or metastatic breast cancer, we investigated whether adipocytes can mediate resistance to doxorubicin (DOX), one of the main drugs used to treat breast cancer, and the mechanisms associated.

Methods: We used a coculture system to grow breast cancer cells with in vitro differentiated adipocytes as well as primary mammary adipocytes isolated from lean and obese patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1088-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337862PMC
January 2019
4 Reads

Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3β activities.

Breast Cancer Res 2019 01 16;21(1). Epub 2019 Jan 16.

Department of Stem Cell & Regenerative Biotechnology and Incurable Disease Animal Model and Stem Cell Institute (IDASI), Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul, 05029, Republic of Korea.

Background: Epithelial-mesenchymal transition (EMT) occurs in the tumor microenvironment and presents an important mechanism of tumor cell intravasation, stemness acquisition, and metastasis. During metastasis, tumor cells enter the circulation to gain access to distant tissues, but how this fluid microenvironment influences cancer cell biology is poorly understood.

Methods And Results: Here, we present both in vivo and in vitro evidence that EMT-like transition also occurs in circulating tumor cells (CTCs) as a result of hydrodynamic shear stress (+SS), which promotes conversion of CD24/CD44/CD133/CXCR4/ALDH1 primary patient epithelial tumor cells into specific high sphere-forming CD24/CD44/CD133/CXCR4/ALDH1 cancer stem-like cells (CSLCs) or tumor-initiating cells (TICs) with elevated tumor progression and metastasis capacity in vitro and in vivo. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1071-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335853PMC
January 2019
8 Reads

Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain.

Breast Cancer Res 2019 01 14;21(1). Epub 2019 Jan 14.

The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK.

Background: Dissemination of breast cancers to the brain is associated with poor patient outcome and limited therapeutic options. In this study we sought to identify novel regulators of brain metastasis by profiling mouse mammary carcinoma cells spontaneously metastasising from the primary tumour in an immunocompetent syngeneic host.

Methods: 4T1 mouse mammary carcinoma sublines derived from primary tumours and spontaneous brain and lung metastases in BALB/c mice were subject to genome-wide expression profiling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13058-018-1093-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332688PMC
January 2019
4 Reads

Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas.

Breast Cancer Res 2019 01 14;21(1). Epub 2019 Jan 14.

Division of General Internal Medicine, Department of Medicine, Institute of Human Genetics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, Box 0320, San Francisco, CA, 94143, USA.

Background: Breast cancer is a partially heritable trait and genome-wide association studies (GWAS) have identified over 180 common genetic variants associated with breast cancer. We have previously performed breast cancer GWAS in Latinas and identified a strongly protective single nucleotide polymorphism (SNP) at 6q25, with the protective minor allele originating from indigenous American ancestry. Here we report on fine mapping of the 6q25 locus in an expanded sample of Latinas. Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1085-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332913PMC
January 2019
16 Reads

Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.

Breast Cancer Res 2019 01 14;21(1). Epub 2019 Jan 14.

Graduate Center Biology Program, Hunter College, City University of New York, Belfer Building, New York, NY, USA.

Introduction: Many human breast cancers overexpress the E3 ubiquitin ligase MDM2 and its homolog MDMX. Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα) breast cancer and triple-negative breast cancer (TNBC). There are p53-independent influences of MDM2 and MDMX, and 80% of TNBC express mutant p53 (mtp53). Read More

View Article

Download full-text PDF

Source
https://breast-cancer-research.biomedcentral.com/articles/10
Publisher Site
http://dx.doi.org/10.1186/s13058-018-1094-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332579PMC
January 2019
11 Reads